Medexus Pharmaceuticals Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MEDXF research report →
Companywww.medexus.com
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy.
- CEO
- Kenneth d'Entremont
- IPO
- 2017
- Employees
- 82
- HQ
- Bolton, ON, CA
Price Chart
Valuation
- Market Cap
- $92.22M
- P/E
- -339.60
- P/S
- 0.93
- P/B
- 1.77
- EV/EBITDA
- 6.48
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 53.87%
- Op Margin
- 2.77%
- Net Margin
- -0.27%
- ROE
- -0.52%
- ROIC
- 2.76%
Growth & Income
- Revenue
- $108.33M · -4.18%
- Net Income
- $2.25M · 1150.00%
- EPS
- $0.08 · 985.26%
- Op Income
- $8.22M
- FCF YoY
- 15.50%
Performance & Tape
- 52W High
- $3.04
- 52W Low
- $1.80
- 50D MA
- $2.67
- 200D MA
- $2.20
- Beta
- 1.82
- Avg Volume
- 9.58K
Get TickerSpark's AI analysis on MEDXF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our MEDXF Coverage
We haven't published any research on MEDXF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MEDXF Report →